Akorn Confirms Generic Durezol(R) Patent Challenge
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Tech selloff weighs down Wall Street as bond yields climb
- Francisco Partners to acquire Weave Communications for $650M
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Goldman Sachs to acquire real estate company LCN for up to $410M
Akorn (AKRX) Report Generic Durezol Patent Challenge
January 15, 2015 5:33 PM ESTAkorn, Inc. (Nasdaq: AKRX), today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market difluprednate ophthalmic emulsion 0.05%. If approved, Akorn's ANDA product would be a generic version of Alcon's Durezol®, which is a topical corticosteroid indicated for the treatment of inflammation and pain associated with... More
